Axitinib, cabozantinib, and lenvatinib are first-line treatment options.
Dane Fritzsche, PharmD, BCOP
Advertisement
Articles by Dane Fritzsche, PharmD, BCOP
New agents can offer a more tailored approach to therapy selection.
Melanoma is responsible for 80% of skin cancer deaths.
Advertisement
Latest Updated Articles
Oral Oncolytics Expand Armamentarium in HR+/HER– Early-Stage Breast Cancer in Adjuvant SettingPublished: October 11th 2022 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Final EMBARK Data Show “Almost Unprecedented” Reduction in Risk of Death With Enzalutamide Plus ADT in Biochemically Recurrent Prostate Cancer
2
From Mutation to Medicine: Targeted Therapies in Lung Cancer
3
Addressing Drug Resistance in Lung Cancer
4
Dato-DXd Doubles Response Rates and Extends Survival in First-Line Metastatic TNBC
5
